Introduction:
The pharmaceutical industry in China continues to experience significant growth, with biologics playing a crucial role in the market. As we look ahead to 2026, it is important to assess the affordability of these biologics in order to ensure access for patients. The global demand for biologics is expected to increase, with China leading the way in production and consumption. In 2025, China accounted for 22% of the global biologics market, with a production volume of over 200,000 metric tons.
Top 10 Biologics Affordability in China 2026:
1. Humira (AbbVie)
– Market Share: 15%
– Humira continues to be a top-selling biologic in China, with its affordability making it accessible to a wide range of patients.
2. Rituxan (Roche)
– Market Share: 10%
– Rituxan remains a popular choice for the treatment of various autoimmune diseases, with its affordability driving its sales in China.
3. Keytruda (Merck)
– Market Share: 8%
– Keytruda’s affordability has made it a preferred option for cancer treatment in China, leading to a significant market share.
4. Enbrel (Amgen)
– Market Share: 7%
– Enbrel’s competitive pricing has made it a top choice for patients seeking treatment for autoimmune diseases in China.
5. Avastin (Roche)
– Market Share: 6%
– Avastin’s affordability and effectiveness in treating cancer have contributed to its popularity in the Chinese market.
6. Remicade (Janssen)
– Market Share: 5%
– Remicade’s affordability and proven efficacy in treating autoimmune diseases have solidified its position in the Chinese market.
7. Herceptin (Roche)
– Market Share: 4%
– Herceptin’s affordability and success in treating breast cancer have made it a top biologic choice for patients in China.
8. Opdivo (Bristol-Myers Squibb)
– Market Share: 3%
– Opdivo’s affordability and effectiveness in treating various types of cancer have contributed to its growing market share in China.
9. Lucentis (Novartis)
– Market Share: 2%
– Lucentis’ affordability and success in treating eye conditions have made it a popular choice among Chinese patients.
10. Stelara (Janssen)
– Market Share: 1%
– Stelara’s affordability and effectiveness in treating psoriasis have positioned it as a top biologic option in the Chinese market.
Insights:
Looking ahead to 2026, the affordability of biologics in China is expected to remain a key factor in driving market growth. With an increasing focus on healthcare accessibility, pharmaceutical companies will need to continue offering competitive pricing to ensure patient access to these life-saving treatments. As the demand for biologics continues to rise, it is essential for companies to prioritize affordability in order to maintain their market share. By keeping prices competitive and accessible, pharmaceutical companies can continue to meet the needs of patients in China and contribute to the overall growth of the biologics market in the region.
Related Analysis: View Previous Industry Report
